Company / Operating Income
BioMarin Pharmaceutical Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$409.5M
FY2025
5-year range
-$82.3M / $484.2M
FY2021-FY2025
Trend
-15.4%
vs FY2024
Sector context
#19 of 204
Health Care
What the data says
Among 204 Health Care companies, BioMarin Pharmaceutical is in the top 9% for operating income. Operating Income has fluctuated over the past 10 years, ranging from -$803M in FY2016 to $484M in FY2024.
Based on SEC 10-K filings.
$409M in FY2025 with a 3-year CAGR of +36.5%. Top quartile in the Health Care sector.
Improved from $186M to $409M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +36.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 204This company $409.5M Sector average $107.7M
▼
+280.1% above sector average
Key checks
Key Insights
- 3-year CAGR of +36.5%, indicating consistent growth.
- In FY2025, operating income decreased 15.4% year-over-year.
- Ranks #19 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $409.5M | -15.4% |
| FY2024 | $484.2M | +160.6% |
| FY2023 | $185.8M | +15.4% |
| FY2022 | $161.0M | +295.5% |
| FY2021 | -$82.3M | -89.6% |
| FY2020 | -$43.4M | +56.8% |
| FY2019 | -$100.5M | +18.7% |
| FY2018 | -$123.5M | -740.3% |
| FY2017 | -$14.7M | +98.2% |
| FY2016 | -$803.4M | -625.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026